Prostate Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Type, By End use, By Region and Competition, 2020-2030F

Description

The Global Prostate Cancer Diagnostics Market, valued at USD 8.92 Billion in 2024, is projected to experience a CAGR of 9.25% to reach USD 15.17 Billion by 2030. Prostate cancer diagnostics encompass a suite of medical procedures and tests employed for the detection, characterization, and staging of prostate cancer, including prostate-specific antigen blood tests, digital rectal examinations, various imaging modalities, and biopsy procedures. The market's expansion is primarily propelled by an aging global demographic, the increasing incidence and prevalence of prostate cancer, growing public awareness coupled with enhanced screening initiatives, and continuous technological advancements in diagnostic methodologies.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 8.92 Billion
Market Size 2030	USD 15.17 Billion
CAGR 2025-2030	9.25%
Fastest Growing Segment	Confirmatory Tests
Largest Market	North America

Key Market Drivers

The increasing global incidence of prostate cancer significantly propels the diagnostics market, as healthcare systems contend with a growing disease burden. This rising prevalence necessitates more frequent and advanced screening, early detection methods, and ongoing monitoring strategies. According to the American Cancer Society, in its January 2024 "Cancer Statistics, 2024" report, nearly 300,000 new cases of prostate cancer were expected in the United States during the year, highlighting the persistent diagnostic demand.

Key Market Challenges

A significant impediment to the expansion of the Global Prostate Cancer Diagnostics Market is the considerable cost associated with advanced diagnostic technologies. These high costs place a substantial financial burden on healthcare systems and individual patients, particularly in regions with developing healthcare infrastructures where budgets are often constrained and reimbursement mechanisms may be insufficient for specialized procedures. This economic barrier directly impacts the ability of healthcare providers to procure and deploy necessary diagnostic equipment and expertise, thus limiting the availability of comprehensive diagnostic services.

Key Market Trends

The Global Prostate Cancer Diagnostics Market is significantly influenced by the decentralization of diagnostic services to outpatient and home settings. This trend represents a fundamental shift in healthcare delivery, moving away from traditional hospital-centric models towards more accessible and convenient diagnostic options. The adoption of at-home collection methods for prostate cancer screening is gaining traction, driven by advancements in non-invasive testing. For instance, in February 2025, Lynx Dx announced the commercial launch of MyProstateScore 2.0 for at-home collection by patients, a test designed to accurately predict the risk of clinically significant prostate cancer using urine samples collected without a digital rectal exam.

Key Market Players

MDx Health, Inc.
Myriad Genetics, Inc.
Abbott Laboratories, Inc.
F. Hoffman-La Roche Ltd.
Siemens Healthcare AG
OPKO Health, Inc.
Exact Sciences Corporation
Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Prostate Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Diagnostics Market, By Test Type:

Preliminary Tests
Confirmatory Tests

Prostate Cancer Diagnostics Market, By Type:

Adenocarcinoma
Interstitial cell carcinoma
Others

Prostate Cancer Diagnostics Market, By End use:

Hospitals & Clinics
Ambulatory Care Centers
Others

Prostate Cancer Diagnostics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Prostate Cancer Diagnostics Market.

Available Customizations:

Global Prostate Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prostate Cancer Diagnostics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Test Type (Preliminary Tests, Confirmatory Tests)
- 5.2.2. By Type (Adenocarcinoma, Interstitial cell carcinoma, Others)
- 5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Prostate Cancer Diagnostics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Test Type
- 6.2.2. By Type
- 6.2.3. By End use
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Prostate Cancer Diagnostics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Test Type
    - 6.3.1.2.2. By Type
    - 6.3.1.2.3. By End use
- 6.3.2. Canada Prostate Cancer Diagnostics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Test Type
    - 6.3.2.2.2. By Type
    - 6.3.2.2.3. By End use
- 6.3.3. Mexico Prostate Cancer Diagnostics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Test Type
    - 6.3.3.2.2. By Type
    - 6.3.3.2.3. By End use

7. Europe Prostate Cancer Diagnostics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Test Type
- 7.2.2. By Type
- 7.2.3. By End use
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Prostate Cancer Diagnostics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Test Type
    - 7.3.1.2.2. By Type
    - 7.3.1.2.3. By End use
- 7.3.2. France Prostate Cancer Diagnostics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Test Type
    - 7.3.2.2.2. By Type
    - 7.3.2.2.3. By End use
- 7.3.3. United Kingdom Prostate Cancer Diagnostics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Test Type
    - 7.3.3.2.2. By Type
    - 7.3.3.2.3. By End use
- 7.3.4. Italy Prostate Cancer Diagnostics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Test Type
    - 7.3.4.2.2. By Type
    - 7.3.4.2.3. By End use
- 7.3.5. Spain Prostate Cancer Diagnostics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Test Type
    - 7.3.5.2.2. By Type
    - 7.3.5.2.3. By End use

8. Asia Pacific Prostate Cancer Diagnostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Test Type
- 8.2.2. By Type
- 8.2.3. By End use
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Prostate Cancer Diagnostics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Test Type
    - 8.3.1.2.2. By Type
    - 8.3.1.2.3. By End use
- 8.3.2. India Prostate Cancer Diagnostics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Test Type
    - 8.3.2.2.2. By Type
    - 8.3.2.2.3. By End use
- 8.3.3. Japan Prostate Cancer Diagnostics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Test Type
    - 8.3.3.2.2. By Type
    - 8.3.3.2.3. By End use
- 8.3.4. South Korea Prostate Cancer Diagnostics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Test Type
    - 8.3.4.2.2. By Type
    - 8.3.4.2.3. By End use
- 8.3.5. Australia Prostate Cancer Diagnostics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Test Type
    - 8.3.5.2.2. By Type
    - 8.3.5.2.3. By End use

9. Middle East & Africa Prostate Cancer Diagnostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Test Type
- 9.2.2. By Type
- 9.2.3. By End use
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Prostate Cancer Diagnostics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Test Type
    - 9.3.1.2.2. By Type
    - 9.3.1.2.3. By End use
- 9.3.2. UAE Prostate Cancer Diagnostics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Test Type
    - 9.3.2.2.2. By Type
    - 9.3.2.2.3. By End use
- 9.3.3. South Africa Prostate Cancer Diagnostics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Test Type
    - 9.3.3.2.2. By Type
    - 9.3.3.2.3. By End use

10. South America Prostate Cancer Diagnostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Test Type
- 10.2.2. By Type
- 10.2.3. By End use
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Prostate Cancer Diagnostics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Test Type
    - 10.3.1.2.2. By Type
    - 10.3.1.2.3. By End use
- 10.3.2. Colombia Prostate Cancer Diagnostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Test Type
    - 10.3.2.2.2. By Type
    - 10.3.2.2.3. By End use
- 10.3.3. Argentina Prostate Cancer Diagnostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Test Type
    - 10.3.3.2.2. By Type
    - 10.3.3.2.3. By End use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Prostate Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. MDx Health, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Myriad Genetics, Inc.
15.3. Abbott Laboratories, Inc.
15.4. F. Hoffman-La Roche Ltd.
15.5. Siemens Healthcare AG
15.6. OPKO Health, Inc.
15.7. Exact Sciences Corporation
15.8. Regeneron Pharmaceuticals Inc.